Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Diagnostic or test agent produces in vivo fluorescence
Reexamination Certificate
2005-01-18
2005-01-18
Jones, Dameron L. (Department: 1616)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Diagnostic or test agent produces in vivo fluorescence
C424S001110, C424S001650, C424S009100
Reexamination Certificate
active
06843980
ABSTRACT:
The present invention provides methods and compositions for imaging cell death in vivo, as well as methods and compositions for tumor radiotherapy.
REFERENCES:
patent: 4671256 (1987-06-01), Lemelson
patent: 5344639 (1994-09-01), Chiu et al.
patent: 5519221 (1996-05-01), Weinberg
patent: 5552525 (1996-09-01), Dean
patent: 5627036 (1997-05-01), Reutelingsperger
patent: 5632986 (1997-05-01), Tait et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 5955437 (1999-09-01), Reutelingsperger
patent: 5965132 (1999-10-01), Thorpe et al.
patent: 5968477 (1999-10-01), Kasina et al.
patent: 5976535 (1999-11-01), Fritzberg et al.
patent: 6004554 (1999-12-01), Thorpe et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6171577 (2001-01-01), Kasina et al.
patent: 6197278 (2001-03-01), Blankenberg et al.
patent: 6261535 (2001-07-01), Thorpe et al.
patent: 6312694 (2001-11-01), Thorpe et al.
patent: 6323313 (2001-11-01), Tait et al.
patent: 6406693 (2002-06-01), Thorpe et al.
patent: WO 9219279 (1992-11-01), None
patent: WO 9410149 (1994-05-01), None
patent: WO 9527903 (1995-10-01), None
patent: WO 9534315 (1995-12-01), None
patent: WO 9617618 (1996-06-01), None
patent: WO 9804294 (1998-02-01), None
patent: WO 0002587 (2000-01-01), None
patent: WO 0002584 A2 (2000-01-01), None
Godar, J. Invest. Dermatology, 1999, vol. 112, pp. 3-12.*
Ohtsuki et al , Eur. J. Nucl. Med., 1999, vol. 26, pp. 1251-1258.*
Blankenberg et al , J. Nucl. Med., Feb. 2001, vol. 42, pp. 309-316.*
Babich, J.W., et al., “Technetium-99m-Labeled Hydrazino Nicotinamide Derivatized Chemotactic Peptide Analogs for Imaging Focal Sites of Bacterial Infection,”The Journal of Nuclear Medicine34(11):1964-1974 (1993).
Barrow, S.A., et al., “Localization of Indium-111-Immunoglobulin G, Technetium-99m-Immunoglobulin G and Indium-111-Labeled White Blood Cells at Sites of Acute Bacterial Infection in Rabbits,”The Journal of Nuclear Medicine34(11):1975-1979 (1993).
Bennett, M.R., et al., “Binding and Phagocytosis of Apoptotic Vascular Smooth Muscle Cells Is Mediated in Part by Exposure of Phosphatidylserine,”Circ. Res.77(6):1136-1142 (1995).
Blankenberg, F.G., et al., “Detection of Apoptotic Cell Death by Proton Nuclear Magnetic Resonance Spectroscopy,”Blood87(5):1951-1956 (1996).
Kasina, S., et al., “Preformed Chelate TC-99m Radiolabeling of r-Annexin V for Arterial Thrombus Imaging,”J. of Nuclear Medicine, Proceedings of the 43rdAnnual Meeting37(5 Supp.):29P Abstract No. 106 (1996).
Koopman, G., et al., “Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis,”Blood84(5):1415-1420 (1994).
Reutelingsperger, C.P.M. et al., “Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis,”Cell. Mol. Life Sci.53:527-532 (1997).
Schwartz, D.A., et al. “Preparation of Hydrazino-Modified Proteins and Their Use for the Synthesis of99mTc-Protein Conjugates,”Bioconjugate Chem.2: 333-336 (1991).
Stratton, J.R., et al., “Selective Uptake of Radiolabeled Annexin V on Acute Porcine Left Atrial Thrombi,”Circulation92: 3113-3121 (1995).
Tait, J.F., et al., “Site-Specific Mutagenesis of Annexin V: Role of Residues from Arg-200 to Lys-207 in Phospholipid Binding,”Archives of Biochem. and Biophys.288(1):141-144 (1991).
Tait, J.F., et al., “Measurement of membrane phospholipid asymmetry in normal and sickle-cell erthrocytes by means of annexin V binding,”J.Lab. Clin. Med.123(5):741-748 (1994).
Tait, J.F., et al., “Phospholipid Binding Properties of Human Placental Anticoagulant Protein-I, a Member of the Lipocortin Family,”The Journal of Biological Chemistry264(14):7944-7949 (1989).
Tait, J.F., et al., “Placental Anticoagulant Proteins: Isolation and Comparative Characterization of Four Members of the Lipocortin Family,”Biochemistry27:6268-6276 (1988).
Tait, J. F., “Clinical Applications of Annexins,”Annexins: Molecular Structure to Cellular Function,ed. Barbara A. Seaton, R.G. Landes Co., pp. 213-220 (1996).
van Heerde, W.L., et al., “The Complexity of the Phospholipid Binding Protein Annexin V,”Thrombosis and Haemostasis73(2):172-179 (1995).
Wood, B.L., et al., “Increased Erythrocyte Phosphatidylserine Exposure in Sickle Cell Disease: Flow-Cytometric Measurement and Clinical Associations,”Blood88(5): 1873-1880 (1996).
Zwaal, R.F.A., et al., “Pathophysiologic Implications of Membrane Phospholipid Asymmetry in Blood Cells,”Blood89(4): 1121-1132 (1997).
Jones Dameron L.
Laccotripe Zacharakis Maria
Lahive & Cockfield LLP
Remillard, Esq. Jane E.
Theseus Imaging, Corp.
LandOfFree
Methods for using annexin for detecting cell death in vivo... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for using annexin for detecting cell death in vivo..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for using annexin for detecting cell death in vivo... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3414126